. 2023 Feb 18;14(2):520. doi: 10.3390/genes14020520

Table 2.

MLST type and antibiotic resistance characteristics of Escherichia coli strains and their corresponding transconjugants.

Strains	Description	MLST	Serotype ^a	Minimum Inhibitory Concentration (μg/mL) ^b														Conjugation Efficiency ^c
Strains	Description	MLST	Serotype ^a	AMP	SAM	ATM	SXT	CIP	TZP	GEN	FEP	CRO	CAZ	CTT	TOB	IPM	LVX	Conjugation Efficiency ^c
E1	donor	ST38	O7:H8	≥32	≥32/16	2	≥16/304	1	64/4	≤1	≥64	≥64	≥64	≥64	≤1	≥16	1	NA
E2	donor	ST58	O?:H37	≥32	≥32/16	≤1	≥16/304	2	64/4	≥16	16	≥64	≥64	≥64	≥16	≥16	1	NA
E3	donor	ST410	O?:H9	≥32	≥32/16	≥64	≥16/304	≥4	≥128/4	≤1	≥64	≥64	≥64	≥64	≥16	4	≥8	NA
E4	donor	ST410	O?:H9	≥32	≥32/16	≥64	≥16/304	≥4	≥128/4	≤1	≥64	≥64	≥64	≥64	≥16	8	≥8	NA
E5	donor	ST410	O?:H9	≥32	≥32/16	4	≥16/304	0.5	≥128/4	≥16	≥64	≥64	≥64	≥64	8	≥16	1	NA
E6	donor	ST131	O25:H4	≥32	≥32/16	≥64	≥16/304	≥4	≥128/4	≥16	≥64	≥64	≥64	≥64	≥16	≥16	≥8	NA
E7	donor	ST361	O9:H30	≥32	≥32/16	16	≥16/304	≥4	≥128/4	≥16	≥64	≥64	≥64	≥64	≥16	≥16	≥8	NA
E8	donor	ST156	O11:H25	≥32	≥32/16	16	≥16/304	2	≥128/4	≤1	≥64	≥64	≥64	≥64	≤1	≥16	2	NA
E1-TC	transconjugant	ST80	O75:H7	≥32	≥32/16	≤1	≤1/19	≤0.25	64/4	≥16	16	≥64	≥64	≥64	≤1	≥16	0.5	2.5 × 10⁻³
E6-TC	transconjugant	ST80	O75:H7	≥32	≥32/16	16	≥16/304	1	≥128/4	≥16	≥64	≥64	≥64	≥64	≥16	16	1	2.9 × 10⁻⁶
E7-TC	transconjugant	ST80	O75:H7	≥32	≥32/16	16	≥16/304	≤0.25	≥128/4	≥16	≥64	≥64	≥64	≥64	≥16	≥16	0.5	3.5 × 10⁻⁶
E8-TC	transconjugant	ST80	O75:H7	≥32	≥32/16	≤1	≤1/19	≤0.25	64/4	≤1	16	≥64	≥64	≥64	≤1	≥16	0.5	1.6 × 10⁻⁶
EC600	recipient	ST80	O75:H7	16	8/4	≤1	≤1/19	≤0.25	≤4/4	≤1	≤1	≤1	≤1	≤4	≤1	≤1	0.5	NA

^a O? indicates that the O serotype of the strain was not typable using the current scheme. ^b Abbreviations: AMP, ampicillin; SAM, ampicillin–sulbactam; ATM, aztreonam; SXT, trimethoprim–sulfamethoxazole; CIP, ciprofloxacin; TZP, piperacillin–tazobactam; GEN, gentamicin; FEP, cefepime; CRO, ceftriaxone; CAZ, ceftazidime; CTT, cefotetan; TOB, tobramycin; IPM, imipenem; LVX, levofloxacin. ^c NA, not applicable.